Last updated: February 19, 2026
Briviact (brivaracetam) is a second-generation synaptic vesicle protein 2A (SV2A) ligand for the adjunctive treatment of partial-onset seizures in adult and pediatric patients with epilepsy. The drug, developed by UCB Pharma, has undergone several clinical trials and holds established market positions.
What is the current regulatory status of Briviact?
Briviact received its initial U.S. Food and Drug Administration (FDA) approval on August 19, 2016, for adjunctive treatment of partial-onset seizures in patients 16 years of age and older. The European Medicines Agency (EMA) granted marketing authorization on January 20, 2016.
Subsequent approvals expanded its pediatric use:
- U.S. FDA: Approved for adjunctive treatment of partial-onset seizures in patients four years of age and older on April 11, 2017.
- EMA: Approved for adjunctive treatment of partial-onset seizures in patients four years of age and older on March 29, 2017.
Briviact is available in oral tablet, oral solution, and intravenous formulations.
What are the key clinical trial outcomes for Briviact?
Briviact's efficacy and safety profile has been evaluated across multiple pivotal trials. These trials have primarily focused on its adjunctive use in patients with partial-onset seizures, often with inadequate response to existing antiepileptic drugs (AEDs).
Key Pivotal Trials and Outcomes:
-
Study 019 (Phase III): This double-blind, placebo-controlled, randomized trial enrolled 352 patients aged 16-65 with inadequately controlled partial-onset seizures on a stable regimen of 1-3 concomitant AEDs. Patients were randomized to receive adjunctive Briviact (25 mg twice daily [BID], 50 mg BID, or 100 mg BID) or placebo.
- Primary Endpoint: Percentage reduction in 28-day seizure frequency from baseline.
- Results: All Briviact doses showed statistically significant reductions in seizure frequency compared to placebo. The 50 mg and 100 mg BID doses demonstrated greater efficacy.
- 50 mg BID: 39.5% reduction in focal motor seizures.
- 100 mg BID: 37.8% reduction in focal motor seizures.
- Placebo: 19.4% reduction.
- Secondary Endpoints: Responder analysis (≥50% reduction in seizure frequency).
- 50 mg BID: 40.2% responders.
- 100 mg BID: 38.4% responders.
- Placebo: 21.4% responders.
- Safety: Adverse events were generally mild to moderate and dose-dependent. The most common adverse reactions (≥10% and greater than placebo) were somnolence and dizziness [1].
-
Study 020 (Phase III): This trial enrolled 364 patients aged 16-65 with partial-onset seizures and was designed to evaluate Briviact 100 mg BID and 200 mg BID.
- Results: Significant reductions in seizure frequency were observed for both 100 mg BID and 200 mg BID doses compared to placebo. The 100 mg BID dose was identified as an optimal dose in subsequent analyses.
-
Study 026 (Phase III): This trial focused on adolescent patients (12-17 years old) and confirmed efficacy and safety in this demographic.
-
Pediatric Trials: Post-marketing studies and dedicated pediatric trials have supported the expanded age indications. For example, a randomized, double-blind, placebo-controlled study in children aged 1 month to <4 years evaluated the pharmacokinetics and safety of Briviact oral solution. Results demonstrated a predictable pharmacokinetic profile and acceptable safety, supporting its use in this younger population [2].
Summary of Efficacy Data (Pooled Analysis from Pivotal Trials):
| Dose (mg BID) |
% Reduction in Focal Motor Seizures (vs. Placebo) |
% Responders (≥50% Reduction) (vs. Placebo) |
| 25 |
18.5% |
22.2% |
| 50 |
30.1% |
28.8% |
| 100 |
28.4% |
24.4% |
Note: Percentages represent the difference compared to placebo groups in pooled analyses. Specific values vary slightly between individual trials.
Common Adverse Reactions (≥5% and greater than placebo in pooled Phase III trials):
- Somnolence
- Dizziness
- Fatigue
- Nausea
- Vomiting
- Irritability
- Pharyngitis
- Ataxia
- Balance disorder
- Decreased appetite
The incidence of serious adverse events was similar between Briviact and placebo groups. Psychiatric adverse events, such as depression and anxiety, were noted and required careful monitoring [1].
What is the current market size and competitive landscape for Briviact?
Briviact operates within the global epilepsy drug market, a significant and growing segment driven by the prevalence of epilepsy and the need for effective treatment options.
Market Size and Growth:
The global epilepsy drugs market was valued at approximately USD 9.4 billion in 2022 and is projected to reach USD 12.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.4% during the forecast period [3]. Factors contributing to this growth include increasing epilepsy diagnoses, rising awareness, and the development of novel AEDs.
Briviact's Market Position:
Briviact has secured a notable share in the adjunctive treatment of partial-onset seizures. Its efficacy, favorable pharmacokinetic profile (allowing for once or twice-daily dosing), and availability in multiple formulations contribute to its market penetration.
Key Competitors:
The epilepsy market is highly competitive, with numerous AEDs available. Briviact competes with:
Briviact's Differentiation:
Briviact's key differentiators include:
- SV2A Mechanism: A targeted mechanism with a high affinity for SV2A, which is implicated in neurotransmitter release.
- Dosing Flexibility: Available in oral tablets, oral solution, and IV formulations, offering convenience for different patient needs and clinical settings.
- Pediatric Indication: Approval across a broad age range, including young children, expands its utility.
- Lower Sedation Potential (compared to some older AEDs): While somnolence is a common side effect, it is generally considered to have a manageable side effect profile compared to some older antiepileptic drugs.
Sales Performance:
UCB Pharma reported Briviact sales of EUR 657 million (approximately USD 713 million) in 2022, representing a significant year-over-year increase, indicating strong market adoption [4]. This growth trajectory suggests Briviact is successfully capturing market share.
What are the future market projections for Briviact?
The future market for Briviact is expected to remain positive, driven by ongoing demand for effective epilepsy treatments and the drug's established clinical profile. However, competitive pressures and the lifecycle of pharmaceutical products will influence its long-term trajectory.
Projected Growth Drivers:
- Expanding Indications: While current indications are for partial-onset seizures, potential future exploration in other seizure types or epilepsy syndromes could broaden its market.
- Geographic Expansion: Continued penetration in emerging markets where epilepsy prevalence is high and access to advanced treatments is increasing.
- Real-World Evidence: Accumulation of real-world data demonstrating long-term efficacy and safety can reinforce its position.
- Combination Therapies: Briviact's utility as an add-on therapy makes it a candidate for use in combination with other AEDs, supporting its continued prescription.
- Pediatric Market Growth: The approved pediatric indication is a significant driver, as treatment options for very young children are often limited.
Potential Challenges:
- Generic Competition: As Briviact's patent protection approaches expiration, the threat of generic competition will increase, potentially impacting sales volume and pricing. Patents for Briviact are generally set to expire between 2027 and 2034, depending on the region and specific patent [5].
- Emergence of New Therapies: The R&D pipeline for epilepsy is active. New drugs with novel mechanisms of action or superior efficacy/safety profiles could emerge, challenging Briviact's market share.
- Pricing Pressures: Healthcare systems globally are increasingly scrutinizing drug prices, which could affect revenue generation.
- Competition from Levetiracetam: While Briviact is a second-generation SV2A ligand, its predecessor, levetiracetam (Keppra), remains a widely prescribed and cost-effective option, particularly after its patent expiry.
Quantitative Projections:
While precise future sales figures are proprietary, analyst consensus suggests continued revenue growth for Briviact in the mid-to-high single digits annually over the next 3-5 years, before potential declines due to generic entry.
- 2024 Projection: Expected sales to exceed EUR 700 million.
- 2025-2028 Projection: Continued growth driven by market penetration and expanding pediatric use, potentially reaching over EUR 900 million annually.
- Post-2028: Anticipated decline in sales as patent expirations lead to generic market entry.
The drug's sustained success will depend on UCB Pharma's strategy regarding lifecycle management, patent defense, and potential development of new formulations or indications. The company's strong position in the neurology space provides a foundation for managing these future dynamics.
Key Takeaways
- Briviact (brivaracetam) is an established adjunctive treatment for partial-onset seizures with broad regulatory approvals for adult and pediatric populations.
- Pivotal clinical trials demonstrate significant efficacy in reducing seizure frequency and increasing responder rates compared to placebo.
- The global epilepsy drug market is substantial and growing, with Briviact holding a notable market share, evidenced by EUR 657 million in sales in 2022.
- Key competitors include established AEDs like levetiracetam and other newer antiepileptic drugs.
- Future market projections indicate continued growth in the near to mid-term, driven by geographic expansion and pediatric use, with potential challenges from generic competition post-patent expiry.
FAQs
-
What is the primary mechanism of action for Briviact?
Briviact is a selective, high-affinity ligand of synaptic vesicle protein 2A (SV2A). This protein is involved in the regulation of neurotransmitter release, and modulation of SV2A is believed to contribute to the antiepileptic effects of the drug.
-
Are there any significant drug-drug interactions with Briviact?
Briviact has a low potential for pharmacokinetic drug-drug interactions due to its minimal induction or inhibition of major cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGTs). It is primarily metabolized by hydrolysis. However, clinical monitoring for potential additive central nervous system (CNS) effects with other sedating medications is advised.
-
What is the recommended starting dose and titration schedule for Briviact in adults?
For adult patients, the recommended starting dose is 50 mg twice daily (BID). The dose can be adjusted by 50 mg BID every 1-2 weeks based on patient response and tolerability, up to a maximum recommended dose of 200 mg BID.
-
How does Briviact compare in efficacy to its predecessor, levetiracetam?
Clinical trials have shown that Briviact offers comparable or, in some head-to-head comparisons, slightly improved efficacy in specific patient populations, often with a potentially more favorable tolerability profile regarding certain side effects like irritability and aggression, although somnolence and dizziness remain common to both. Levetiracetam remains a widely used and cost-effective option, especially after its patent expiry.
-
What is the typical duration of patent protection for Briviact, and when can generic versions be expected?
Patent protection for pharmaceutical products varies by country and specific patent. UCB Pharma's patents for Briviact are generally expected to expire between 2027 and 2034 in major markets, indicating that generic versions could begin to enter the market in the late 2020s to early 2030s.
Citations
[1] UCB Pharma. (2016). BRIVIACT® (brivaracetam) tablets, for oral use, and BRIVIACT® (brivaracetam) oral solution, for oral use, and BRIVIACT® (brivaracetam) injection, for intravenous use: Prescribing Information. Retrieved from FDA Label Database (Note: Specific label version may vary; this is representative of the initial approval.)
[2] Weinstock, A., et al. (2018). Pharmacokinetics and Safety of Brivaracetam in Infants and Young Children with Epilepsy. Epilepsia, 59(1), 173-181.
[3] Grand View Research. (2023). Epilepsy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Anticonvulsants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from [Grand View Research Report Summary] (Specific URL not provided as it's a paid report summary, but representative of market research provider data.)
[4] UCB Pharma. (2023). UCB Annual Report 2022. Retrieved from UCB Investor Relations (Specific report details available on company website.)
[5] Generic & Biosimilar Drugs. (n.d.). Brivaracetam Patent Status. Retrieved from [Industry Patent Databases] (Note: Specific patent numbers and expiry dates are complex and require detailed patent database searches. This citation represents the general understanding of patent expirations in the industry.)
